Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety and pharmacokinetics after
administration of 10mg/kg TA-650 every 8 weeks to patients with Crohn's disease showing an
insufficient response to previous treatment with 5 mg/kg of REMICADE every 8 weeks.